Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma

Inclusion Criteria: 1. Patients aged ≥ 18 year-old. 2. Histologically documented renal cell carcinoma whatever the type. 3. One or two prior therapy with cytokines and/or VEFG-ligand inhibitors are permitted. 4. Patients with an indication to receive everolimus treatment 5. Patients able and willing to give written informed consent, before the first screening procedure. Exclusion Criteria: 1. Patients currently receiving chemotherapy or immunotherapy 2. Prior treatment with temsirolimus 3. Contraindication in everolimus : * Hypersensitivity to the active substance, to other rapamycin derivatives or to any of the excipients. * Patients with severe hepatic impairment (Child-Pugh class C) * Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. 4. Pregnant or breastfeeding women 5. Patients unwilling to or unable to comply with the protocol.